Overview
Claudia Feriotti practices practicing medicine in Sao Paulo, Brazil.
Ms. Feriotti is highly rated in 1 condition, according to our data. Her clinical expertise encompasses Paracoccidioidomycosis and Immunodeficiency with Hyper IgM Type 1.
She is actively involved in clinical research, co-authoring 18 peer reviewed articles.
Gender
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Claudia Feriotti
Is Claudia Feriotti a top-rated expert for Paracoccidioidomycosis?
MediFind is an objective health platform that identifies experts based on real-world data. Claudia Feriotti is classified as an Elite expert for Paracoccidioidomycosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Claudia Feriotti participate in research or clinical trials?
Yes. Claudia Feriotti has published 18 articles and abstracts on conditions like Paracoccidioidomycosis. You can view a list of Claudia Feriotti's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Elite
- ParacoccidioidomycosisMs. Feriotti isElite. Learn about Paracoccidioidomycosis.
- Experienced
- Immunodeficiency with Hyper IgM Type 1Ms. Feriotti isExperienced. Learn about Immunodeficiency with Hyper IgM Type 1.